Evaluating the likelihood of pediatric sacral nerve stimulator explantations due to cure or complications: a survival analysis of 13-year institutional cohort - Scorecard - MDSpire
Advertisement
Evaluating the likelihood of pediatric sacral nerve stimulator explantations due to cure or complications: a survival analysis of 13-year institutional cohort
Clinical Scorecard: Assessing the Probability of Sacral Nerve Stimulator Removal in Pediatric Patients: A 13-Year Survival Analysis from an Institutional Cohort
At a Glance
Category
Detail
Condition
Pediatric bladder bowel dysfunction (BBD) refractory to conventional therapies
Key Mechanisms
Sacral nerve modulation (SNM) delivers mild electrical impulses to sacral nerves to modulate bladder activity and restore functional voiding
Target Population
Children under 18 years with refractory BBD after ≥ 2 years of conventional management
Care Setting
Specialized pediatric urology centers with capability for SNM implantation and follow-up
Key Highlights
Approximately 70–80% of pediatric SNM recipients experience significant symptom improvement; up to 40% achieve complete symptom resolution.
Median time to SNM explantation was 6 years; 72.3% of explantations were due to symptom resolution (cure), 27.7% due to complications.
Among patients explanted for cure, 94.4% had sustained symptom resolution at median 3.8 years post-explantation without medications.
Guideline-Based Recommendations
Diagnosis
Confirm refractory BBD after failure of behavioral, dietary, pelvic physiotherapy, constipation management, and pharmacotherapy for ≥ 2 years.
Perform spinal MRI to exclude occult spina dysraphism before SNM consideration.
Management
Offer SNM trial stage with >50% symptom improvement over 2 weeks before permanent implantation.
Consider SNM for pediatric patients refractory to conventional therapies and after neurosurgical evaluation if indicated.
Turn off SNM device after 1 year of complete symptom resolution and consider explantation after ≥ 6 months of sustained resolution.
Monitoring & Follow-up
Close follow-up post-implantation to assess symptom improvement and device function.
Monitor for complications such as infection, pain, MRI requirements, and clinical inefficacy.
Post-explantation follow-up to assess sustained symptom resolution and medication use.
Risks
Device-related complications including infection, pain at implantation site, MRI incompatibility, and clinical inefficacy.
Approximately 27.7% of explantations were due to complications, mostly occurring within first 3 years.
Patient & Prescribing Data
Pediatric patients with refractory bladder bowel dysfunction undergoing SNM therapy
Most patients achieving cure post-explantation do not require ongoing pharmacotherapy; a minority may need medications such as mirabegron or oxybutynin for mild symptom recurrence.
Clinical Best Practices
Ensure thorough counseling and informed consent regarding off-label use of SNM in pediatric patients.
Use a staged approach with trial stimulation before permanent SNM implantation.
Implement multidisciplinary evaluation including neurosurgical assessment when spinal abnormalities are suspected.
Offer device explantation after sustained symptom resolution to minimize long-term device-related risks.
Maintain long-term follow-up to monitor for symptom recurrence and manage accordingly.
by Jin Kyu Kim, Konrad M. Szymanski, Rosalia Misseri, Shelly J. King, Nikhil V. Batra, Martin Kaefer, Mark P. Cain, Richard C. Rink, Joshua Roth, Pankaj Dangle, Kirstan Meldrum, Benjamin M. Whittam
Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties
